Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week extension study of EVP-6124 in Alzheimer's disease
NL-OMON41994Phase 3Active, not recruiting
- Sponsor
- FORUM Pharmaceuticals
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of encenicline in Alzheimer's disease (AD) and Dementia (2 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Vital signs and 5 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON41994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41994.